State of Wyoming’s Y-mAbs Therapeutics YMAB Stock Holding History

State of Wyoming’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-15	Closed	-$82	–	1841
2023 Q3	$82	Buy	+15	New	+$87	﹤0.01%	1586

Other funds holding YMAB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

State of Wyoming's YMAB Position: Q4 2023 in Review

State of Wyoming sold out of Y-mAbs Therapeutics (YMAB) in Q4 2023, closing a stake of 15 shares — an estimated $82 sold.

State of Wyoming first reported a position in YMAB in Q3 2023 and held it in 1 quarter. The position peaked at $82 in Q3 2023. 94 funds tracked by Wall St. Rank hold YMAB as of Q4 2023.

State of Wyoming reported no remaining Y-mAbs Therapeutics position as of Q4 2023 after selling out during the quarter.
State of Wyoming sold 15 Y-mAbs Therapeutics shares in Q4 2023, an estimated $82.
State of Wyoming first reported a position in Y-mAbs Therapeutics in Q3 2023 and held it in 1 quarter.
State of Wyoming's Y-mAbs Therapeutics position peaked at $82 in Q3 2023.
94 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2023.

Based on State of Wyoming's 13F filing for Q4 2023, filed 15 Feb 2024.